CN112716992A - Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof Download PDFInfo
- Publication number
- CN112716992A CN112716992A CN202110104132.9A CN202110104132A CN112716992A CN 112716992 A CN112716992 A CN 112716992A CN 202110104132 A CN202110104132 A CN 202110104132A CN 112716992 A CN112716992 A CN 112716992A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- heart disease
- product
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
The invention provides a traditional Chinese medicine composition for treating coronary heart disease and a preparation method thereof, and the raw materials comprise the following components in parts by weight: 5-25 parts of dalbergia wood, 5-25 parts of angelica and 5-40 parts of ligusticum wallichii. The traditional Chinese medicine composition can relieve clinical symptoms such as precordial distress, swelling, pain and the like of patients with coronary heart disease, has a good effect of improving myocardial blood supply, has an effective rate of up to 90.4%, and provides a new choice for clinical medication.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating coronary heart disease and a preparation method thereof.
Background
Coronary Heart Disease (CHD), the most common heart disease, refers to myocardial dysfunction and/or organic degeneration caused by coronary stenosis and insufficient blood supply, and is also called ischemic cardiomyopathy (lHD). Coronary heart disease is a high incidence disease in China, and is the fastest to rise in the constitution of resident death causes, so that coronary heart disease becomes an important disease threatening the public health of China. Therefore, the research on how to prevent and treat coronary heart disease is an important subject in the medical field.
Current treatments for coronary heart disease include: life habits change: smoking cessation and alcohol restriction, low-fat and low-salt diet, proper physical exercise, weight control and the like; ② medicine treatment: antithrombotic (anti-platelet, anticoagulant), reducing myocardial oxygen consumption (beta receptor blocker), relieving angina (nitrate), regulating lipid and stabilizing plaque (statin lipid regulating drug); ③ revascularization treatment: including interventional procedures (endovascular balloon angioplasty and stenting) and surgical coronary artery bypass grafting. Drug therapy is the basis of all treatments, and long-term standard drug therapy is adhered to after surgical treatment. For the same patient, although the available medicines can be ideally controlled in one stage of the disease, the single-medicine treatment effect is often poor in the other stage, the medicines need to be combined with interventional therapy or surgical operation, and long-term use of the western medicines can not only produce side effects on the body, but also produce drug resistance. Under the common conditions, the traditional Chinese medicine is adopted for long-term treatment, has safety, less side effect, less stimulation to liver and kidney and no damage to gastrointestinal tract.
Although there is no name for coronary heart disease in traditional Chinese medicine, according to the literature, many symptoms similar to coronary heart disease are described, such as "chest impediment", "heart and stomach disease", "chest pain", "true heart pain", "jue heart pain", and the like. Su Wen & visceral Qi method theory Yun: for heart disease, pain in the chest, fullness in the hypochondrium, hypochondriac pain, pain between the shoulders and feet of the back and back, pain in the arms. The traditional Chinese medicine holds that the pathogenesis of the coronary heart disease is not limited by liver and kidney deficiency, turbid phlegm and blood stasis to cause heart vessel blockage and unsmooth running, and the disease is mostly the syndrome of deficiency in origin and marked excess, and is accompanied by deficiency and excess. According to the types, each family can obtain better curative effect as long as the syndrome differentiation is accurate and the medicine is properly used. Therefore, the traditional Chinese medicine also becomes the preferred choice of patients with coronary heart disease, and if a new compound preparation for effectively treating coronary heart disease can be developed in the traditional Chinese medicine, a new choice is provided for clinical medication of coronary heart disease in China.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating coronary heart disease and a preparation method thereof, which can relieve clinical symptoms of patients with coronary heart disease, such as precordial distress, swelling, pain and the like, and have good effect of improving myocardial blood supply.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
a traditional Chinese medicine composition comprises the following raw materials in parts by weight: 5-25 parts of dalbergia wood, 5-25 parts of angelica and 5-40 parts of ligusticum wallichii.
In a specific embodiment of the invention, the raw materials comprise the following components in parts by weight: 10-20 parts of dalbergia wood, 10-20 parts of angelica and 10-30 parts of ligusticum wallichii.
In a specific embodiment of the invention, the raw materials comprise the following components in parts by weight: 20 parts of dalbergia wood, 10 parts of angelica and 30 parts of ligusticum wallichii;
or comprises 10 parts of dalbergia wood, 20 parts of angelica and 10 parts of ligusticum wallichii.
The invention combines dalbergia wood, angelica and ligusticum wallichii, and the medicines are combined to generate a synergistic effect, so that the precordial distress and swelling, pain and the like can be relieved, the acute attack frequency of the coronary heart disease of a patient can be effectively reduced, and the invention has a good effect of improving myocardial blood supply.
Wherein:
lignum Dalbergiae Odoriferae is dried heartwood of trunk and root of Dalbergia odorifera;
radix Angelicae sinensis is dried root of Angelica sinensis;
the rhizoma Ligustici Chuanxiong is dried rhizome of Ligusticum chuanxiong Hort.
The inventor finds that the surface area of the medicinal powder is large when the raw powder is used for medicine application, the medicinal powder is also beneficial to slow release of active ingredients in the medicinal materials, and the action time is long, but the inventor further finds that the active ingredients still need to be dissolved and absorbed in vivo without extracting the medicinal materials, so that the toxic and side effects of harmful ingredients in the medicinal materials on human bodies are weakened, but the effect is slow, the medicinal powder is suitable for long-term administration, and the raw powder is prepared into administration forms such as pills, capsules and the like; the medicinal materials are extracted and prepared into other administration forms such as transdermal absorption preparations, external lotion, in-vivo implanted preparations, injection and the like, so that the toxic and side effects are less, the targeting property of the medicine can be enhanced, and the medicine effect can be improved.
Another object of the present invention is to provide a method for preparing the above-mentioned Chinese medicinal composition, which comprises the following steps: the raw materials are combined according to the weight portion.
The present invention includes one or more of the following items (1) to (3):
(1) taking the powder of each raw medicinal material; (2) mixing; (3) extracting;
further, the solvent for extraction is water or alcohol;
further, the alcohol is 40-95% v/v ethanol water solution, preferably 50-80% v/v ethanol water solution.
Wherein, the (1) can be combined with any one or two of the (2) and (3), and the raw medicinal materials in the (1) can be respectively and independently selected from any one or two of the (2) and (3) and the dalbergia wood, the angelica and the hemlock parsley, or can be selected from a plurality of dalbergia wood, the angelica and the hemlock parsley and then combined with any one or two of the (2) and (3) and the like; can be directly mixed with medicinal powder; or making into extract; or mixing part of the above extracts and part of the above medicinal powders.
That is, the following combinations may be included but not limited to:
A. mixing at least two components of the raw material medicinal powder and extracting;
B. respectively and independently extracting the powder of each raw material medicine and then mixing;
for example, mixing lignum Dalbergiae Odoriferae, radix Angelicae sinensis, and rhizoma Ligustici Chuanxiong; or mixing lignum Dalbergiae Odoriferae and radix Angelicae sinensis, extracting rhizoma Ligustici Chuanxiong separately, and mixing; or mixing lignum Dalbergiae Odoriferae and rhizoma Ligustici Chuanxiong, extracting, and mixing with radix Angelicae sinensis component; or mixing radix Angelicae sinensis and rhizoma Ligustici Chuanxiong, extracting lignum Dalbergiae Odoriferae separately, mixing, etc.
Another object of the present invention is to provide a use of the above composition for the preparation of a product for preventing and/or treating heart disease;
further, the heart disease is coronary heart disease;
furthermore, the product is a product for improving suffocating and pain caused by coronary heart disease.
The invention also aims to provide application of the composition in preparing a product for preventing and/or treating myocardial ischemia.
The invention also aims to provide a product, the active ingredients of which comprise the traditional Chinese medicine composition;
further, the preparation form of the product is selected from one or more of gastrointestinal absorption preparation, transdermal absorption preparation, in-vivo implantation preparation and injection; the preferred form of the formulation is a gastrointestinal absorption formulation.
Furthermore, the formulation of the gastrointestinal absorption preparation is selected from powder, tablets, granules, paste, powder, capsules, pills and oral liquid, and further is tablets and granules.
The active ingredients can be mixed with pharmaceutically acceptable auxiliary materials to prepare a product; by "pharmaceutically acceptable" is meant any substance that does not interfere with the effectiveness of the biological activity of the active ingredient and is not toxic to the host to which it is administered.
The pharmaceutically acceptable auxiliary materials are general names of all the additional materials except the main medicine in the medicine, and the auxiliary materials have the following properties: (1) no toxic effect on human body and few side effects; (2) the chemical property is stable and is not easily influenced by temperature, pH, storage time and the like; (3) has no incompatibility with the main drug, and does not influence the curative effect and quality inspection of the main drug; (4) does not interact with the packaging material. The auxiliary materials in the invention include, but are not limited to, a filler (diluent), a lubricant (glidant or anti-adhesion agent), a dispersing agent, a wetting agent, an adhesive, a regulator, a solubilizer, an antioxidant, a bacteriostatic agent, an emulsifier, a disintegrating agent and the like. The binder comprises syrup, acacia, gelatin, sorbitol, tragacanth, cellulose and its derivatives (such as microcrystalline cellulose, sodium carboxymethylcellulose, ethyl cellulose or hydroxypropyl methylcellulose), gelatin slurry, syrup, starch slurry or polyvinylpyrrolidone; the filler comprises lactose, sugar powder, dextrin, starch and its derivatives, cellulose and its derivatives, inorganic calcium salt (such as calcium sulfate, calcium phosphate, calcium hydrogen phosphate, precipitated calcium carbonate, etc.), sorbitol or glycine, etc.; the lubricant comprises superfine silica gel powder, magnesium stearate, talcum powder, aluminum hydroxide, boric acid, hydrogenated vegetable oil, polyethylene glycol and the like; the disintegrating agent comprises starch and its derivatives (such as sodium carboxymethyl starch, sodium starch glycolate, pregelatinized starch, modified starch, hydroxypropyl starch, corn starch, etc.), polyvinylpyrrolidone or microcrystalline cellulose, etc.; the wetting agent comprises sodium lauryl sulfate, water or alcohol, etc.; the antioxidant comprises sodium sulfite, sodium bisulfite, sodium pyrosulfite, dibutylbenzoic acid, etc.; the bacteriostatic agent comprises 0.5% of phenol, 0.3% of cresol, 0.5% of chlorobutanol and the like; the regulator comprises hydrochloric acid, citric acid, potassium (sodium) hydroxide, sodium citrate, and buffer (including sodium dihydrogen phosphate and disodium hydrogen phosphate); the emulsifier comprises polysorbate-80, sorbitan fatty acid, pluronic F-68, lecithin, soybean lecithin, etc.; the solubilizer comprises Tween-80, bile, glycerol, etc.
Further, the preparation method of the product comprises the following steps: mixing the above Chinese medicinal composition with adjuvants, and making into product.
The invention has the following beneficial effects:
(1) the product prepared from the composition consisting of the dalbergia wood extract, the angelica sinensis extract and the ligusticum wallichii extract has high drug effect, avoids unnecessary toxic and side effects, can relieve the clinical symptoms of patients with coronary heart disease, such as precordial distress, pain and the like, has good effect of improving myocardial ischemia, has the effective rate of up to 90.4 percent, and provides a new choice for clinical medication.
(2) The preparation method has the advantages of simple preparation process, mild conditions and easy control.
Detailed Description
The present invention is further illustrated by the following examples and specific tests. The following examples are only preferred embodiments of the present invention and are not intended to limit the present invention, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Example 1 preparation of the composition
Removing impurities from the traditional Chinese medicine raw materials, cleaning, drying, carefully selecting 20g of traditional Chinese medicine dalbergia wood, 10g of angelica and 30g of ligusticum wallichii according to required weight, mixing and crushing, decocting twice with water, wherein the decocting time is 40min each time, 10-15 times of water each time, combining water extract, concentrating into thick paste, drying, grinding, preparing into granules, and bagging to obtain the granules, wherein the mass of the content in each bag is 6 g.
Example 2 preparation of the composition
Removing impurities from the traditional Chinese medicine raw materials, cleaning, drying, carefully selecting 20g of rosewood heart wood, 15g of angelica and 15g of ligusticum wallichii according to the required weight, carrying out reflux extraction for 2 times by using 50-80% ethanol, extracting for 1h each time, and combining ethanol extract; decocting the residue in water for 2 times (each time for 30 min), mixing the decoctions, recovering ethanol from the ethanol extractive solution, mixing with the water decoction, precipitating, concentrating, adding 10 parts of starch, and tabletting to obtain tablet.
Example 3 preparation of the composition
Removing impurities from the traditional Chinese medicine raw materials, cleaning, drying, carefully selecting 20g of rosewood heart wood, 15g of angelica and 15g of ligusticum wallichii according to the required weight, carrying out reflux extraction for 2 times by using 50-80% ethanol, extracting for 1 hour each time, combining ethanol extract, and recovering ethanol at low temperature to obtain extracted oil; decocting the residue in water for 2 times (each time for 30 min), mixing the decoctions, concentrating, drying, pulverizing into fine powder, mixing with the extract oil, and making into capsule.
Test example 1
Statistics of clinical data effects
Patient gender and age range: the disease is male and female, the age range is 48-85 years, and the history of coronary heart disease is different from 1 month to nearly 30 years. 105 patients were treated at the clinic.
The current medical history of the patient is mainly intermittent precordial oppression and distension, pain and the like. It is usually intermittent and repeated. Electrocardiogram representation: frequent or sporadic ventricles.
The curative effect standard is as follows:
(1) the clinical symptoms and physical signs are obviously improved, and the electrocardiogram is recovered to be normal or approximately normal (namely normal range electrocardiogram).
(2) Effective clinical symptoms and physical signs are all improved, the electrocardiogram S-T section is reduced and rises back by more than 0.05mV after treatment, but does not reach the normal level, the T wave changes to be shallow (more than 25 percent) or the T wave changes from flat to upright in the inversion of main leads, and atrioventricular or indoor conduction block is improved.
(3) The clinical symptoms and physical signs are not obviously improved or even aggravated, and the electrocardiogram is basically the same as before the treatment.
The treatment method comprises the following steps:
the granules prepared in the embodiment 1 of the invention are orally taken for 2 bags each time, 2 times a day and 1 month as 1 course of treatment.
The treatment effect is as follows:
the effect is obvious in 30 cases, the effect reaches 33.3 percent, clinical symptoms disappear, and the disease does not occur in 3 months;
the curative effect of 60 cases is obvious, about 57.1 percent, the clinical symptoms are relieved, and the number of acute attack times within 3 months is obviously reduced;
15 of the cases were ineffective, accounting for about 14.3%.
Combining the above results, the total effective rate of the pharmaceutical composition of the invention is 90.4%.
Specific case examples are as follows:
case 1:
patient guo, male, 65 years old; the diagnosis is frequently performed in the early ventricular stage in Shanxi province cardiovascular disease hospitals mainly due to the precordial distress and distension and palpitation, and the CT radiography shows that the obstruction of the main artery of the coronary artery is less than 25 percent and the obstruction of the small artery is less than 50 percent. The dynamic electrocardiogram room is more than 10000 times per day early. After the granules prepared in example 1 are taken for treatment for one month, precordial suffocating feeling is obviously relieved, palpitation and discomfort are still happened, the frequency is obviously reduced compared with the former frequency, and the dynamic electrocardiogram room is reduced to about 5000 early.
After the composition consisting of the dalbergia wood extract, the Chinese angelica extract and the ligusticum wallichii extract is used in a compatible manner, most of clinical symptoms of patients with coronary heart disease, such as precordial labored distension, pain and the like, can be obviously relieved, the acute attack frequency of the coronary heart disease of the patients can be effectively reduced, the effective rate is up to 90.4%, and a new choice is provided for clinical medication.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all modifications of equivalent structures and equivalent processes, which are made by the present specification, or directly or indirectly applied to other related technical fields, are included in the scope of the present invention.
Claims (10)
1. The traditional Chinese medicine composition is characterized by comprising the following raw materials in parts by weight: 5-25 parts of dalbergia wood, 5-25 parts of angelica and 5-40 parts of ligusticum wallichii.
2. The traditional Chinese medicine composition according to claim 1, wherein the raw materials comprise the following components in parts by weight: 10-20 parts of dalbergia wood, 10-20 parts of angelica and 10-30 parts of ligusticum wallichii.
3. The traditional Chinese medicine composition according to claim 1, wherein the raw materials comprise the following components in parts by weight: 20 parts of dalbergia wood, 10 parts of angelica and 30 parts of ligusticum wallichii;
or comprises 10 parts of dalbergia wood, 20 parts of angelica and 10 parts of ligusticum wallichii.
4. The preparation method of the traditional Chinese medicine composition according to any one of claims 1 to 3, which comprises the following steps: the raw materials are combined according to the weight portion.
5. The method according to claim 4, characterized by comprising one or more of the following (1) to (3):
(1) taking the powder of each raw medicinal material; (2) mixing; (3) extracting;
further, the solvent for extraction is water or alcohol;
further, the alcohol is 40-95% v/v ethanol water solution, preferably 50-80% v/v ethanol water solution.
6. Use of a composition according to any one of claims 1 to 3 for the preparation of a product for the prevention and/or treatment of heart disease;
further, the heart disease is coronary heart disease;
furthermore, the product is a product for improving suffocating and pain caused by coronary heart disease.
7. Use of the composition of any one of claims 1 to 3 for the preparation of a product for the prevention and/or treatment of myocardial ischemia.
8. A product, characterized in that the active ingredient comprises the Chinese medicinal composition of any one of claims 1 to 3;
further, the preparation form of the product is selected from one or more of gastrointestinal absorption preparation, transdermal absorption preparation, in-vivo implantation preparation and injection; the preferred form of the formulation is a gastrointestinal absorption formulation.
9. The product according to claim 8, wherein the formulation of the gastrointestinal absorption preparation is selected from the group consisting of powder, tablet, granule, paste, powder, capsule, pill, oral liquid, further tablet, granule.
10. A process for the preparation of a product according to claim 8 or 9, characterized in that it comprises the following steps: mixing the Chinese medicinal composition of any one of claims 1 to 3 to prepare a product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110104132.9A CN112716992A (en) | 2021-01-26 | 2021-01-26 | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110104132.9A CN112716992A (en) | 2021-01-26 | 2021-01-26 | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112716992A true CN112716992A (en) | 2021-04-30 |
Family
ID=75593553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110104132.9A Pending CN112716992A (en) | 2021-01-26 | 2021-01-26 | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112716992A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102038726A (en) * | 2009-10-10 | 2011-05-04 | 上海医药工业研究院 | Method for preparing organic acid part purified from angelica sinensis-ligusticum wallichii supercritical CO2 extractive |
| CN102526189A (en) * | 2012-02-20 | 2012-07-04 | 许从玉 | Chinese medicinal composition for treating angina pectoris |
| CN104415085A (en) * | 2013-09-03 | 2015-03-18 | 上海祥鹤药业有限公司 | Preparation method of ligusticum wallichii and dalbergia wood dry extract for Kuanxin capsules |
| CN104873685A (en) * | 2015-06-02 | 2015-09-02 | 周红玲 | Medicine for treating coronary heart disease |
-
2021
- 2021-01-26 CN CN202110104132.9A patent/CN112716992A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102038726A (en) * | 2009-10-10 | 2011-05-04 | 上海医药工业研究院 | Method for preparing organic acid part purified from angelica sinensis-ligusticum wallichii supercritical CO2 extractive |
| CN102526189A (en) * | 2012-02-20 | 2012-07-04 | 许从玉 | Chinese medicinal composition for treating angina pectoris |
| CN104415085A (en) * | 2013-09-03 | 2015-03-18 | 上海祥鹤药业有限公司 | Preparation method of ligusticum wallichii and dalbergia wood dry extract for Kuanxin capsules |
| CN104873685A (en) * | 2015-06-02 | 2015-09-02 | 周红玲 | Medicine for treating coronary heart disease |
Non-Patent Citations (3)
| Title |
|---|
| 穆瑞兰，等: "化瘀通脉注射液治疗缺血性中风偏瘫临床对比观察", 《中医药研究》 * |
| 郭涛，等: "心舒口服液对大鼠主动脉血管平滑肌细胞增殖和家兔体外血小板聚集功能的影响", 《中国药学杂志》 * |
| 鲁建武，等: "HPLC法同时测定复方川芎胶囊中阿魏酸和川芎嗪含量", 《中国药师》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1905444A1 (en) | Medicinal composition containing ginseng secondary glycosides, its preparation method and application | |
| CN101632796B (en) | Application of Chinese medicinal composition in preparing medicament for treating acute heart failure | |
| US10849950B2 (en) | Composition for treating fatty liver | |
| JPH0651636B2 (en) | New anticancer drug | |
| CN108310199A (en) | A kind of Chinese medicine composition and its preparation for treating coronary disease and angina pectoris | |
| CN111888396B (en) | Pharmaceutical composition for treating cervical spondylosis and preparation method and application thereof | |
| CN102228535B (en) | Application of total saponins and total flavones in preparation of drugs for treating cardiovascular diseases | |
| TW201106959A (en) | Composition for preventing or treating irritable bowel syndrome | |
| CN101099775B (en) | Cardiac and cerebral vascular disease treating medicine | |
| CN101152223B (en) | Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease | |
| CN112716992A (en) | Traditional Chinese medicine composition for treating coronary heart disease and preparation method thereof | |
| CN103784683B (en) | A kind of Chinese medicine composition treating obesity and its preparation method and application | |
| CN106620253B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia | |
| CN102258600B (en) | Medicine composition for treating cardiovascular disease | |
| CN103055122A (en) | Medicine for preventing restenosis after intracoronary stent implantation and preparation method thereof | |
| CN109758497A (en) | For the Chinese medicine composition of chronic heart failure, drug and its preparation method and application | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN115429836B (en) | Traditional Chinese medicine preparation for treating arrhythmia | |
| CN114931600B (en) | Traditional Chinese medicine composition for preventing and treating altitude stress and preparation method thereof | |
| CN113144119A (en) | Traditional Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof | |
| CN108079055B (en) | Combination of traditional Chinese medicine composition and sorafenib and application of combination in preparation of medicine for treating liver cancer | |
| CN105267470B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating coronary heart disease | |
| CN112656919A (en) | A Chinese medicinal composition for treating hyperlipidemia and fatty liver, and its preparation method | |
| CN105998611B (en) | A kind of pharmaceutical composition and preparation method and application | |
| CN105477384A (en) | Traditional Chinese medicine composition capable of reducing blood pressure and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210430 |
|
| RJ01 | Rejection of invention patent application after publication |